Neuroone Medical Technologies (NMTC) Debt Ratio (2010 - 2024)

Neuroone Medical Technologies (NMTC) reported Debt Ratio of 0.02 for Q1 2024, up 41.7% sequentially from 0.02 in Q3 2023.

Neuroone Medical Technologies (NMTC) Debt Ratio (2010 - 2024) Analysis & Trends

Neuroone Medical Technologies has disclosed Debt Ratio across 9 years of filings, most recently posting 0.02 for Q1 2024.

Quarterly Debt Ratio changed N/A year-over-year to 0.02 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was 0.02 (changed N/A YoY) and the FY2023 annual result came in at 0.02, changed N/A from the prior year.
Debt Ratio improved to 0.02 in Q1 2024, from 0.02 in the prior quarter.
Across five years, Debt Ratio topped out at 0.02 in Q1 2024 and bottomed at 0.02 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.31
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.32
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.31
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.04
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.30
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.27
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.18
10	Neuroone Medical Technologies	26.73 Mn	23.93 Mn	990,264.00	-

Download Data